CatalystAlertBeta

Briefing Calendar News IPOs Opportunities Companies Compare Analytics Watchlist Learn

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Short Interest
Smart Money
Biotech Glossary

Legal

About
ML Track Record
Privacy
Terms
Cookies

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

Follow Us

⚠️ Important Legal Disclaimer

Not Financial Advice: CatalystAlert is an informational platform only. We are NOT a registered investment advisor, broker, or dealer. The information provided on this website does not constitute investment advice, financial advice, trading advice, or any other sort of advice, and you should not treat any of the website's content as such.

No Guarantees: All predictions, probability scores, and analyses are based on historical data and machine learning models. Past performance does NOT guarantee future results. Biotech investing is extremely high-risk and you may lose your entire investment.

Data Accuracy: While we strive for accuracy, data may be incomplete, delayed, or contain errors. We aggregate data from third-party sources (FDA, SEC, ClinicalTrials.gov) and are not responsible for their accuracy. Always verify information with official sources before making any decisions.

Your Responsibility: You are solely responsible for your investment decisions. Consult a qualified financial advisor before investing. CatalystAlert and its operators accept no liability for any losses incurred from using this platform.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

Home Calendar News Learn Account

Glofitamab - Phase 3 | RHHBY Pipeline | CatalystAlert

Glofitamab

Phase 3

Roche Holding AG (RHHBY)

00%

Phase 3

Development Phase

3

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

12mo

RHHBYPhase 3$344.8B

Glofitamab Phase 3 Results Expected

Glofitamab• Diffuse Large B-cell Lymphoma182

Feb 26Estimated

00%

11mo

RHHBYPhase 2$344.8B

Glofitamab Phase 2 Results Expected

Glofitamab• Diffuse Large B-cell Lymphoma100

Jan 31Estimated

00%

7mo

RHHBYPhase 2$344.8B

Glofitamab Phase 2 Results Expected

Glofitamab• Diffuse Large B-cell Lymphoma46

Sep 30Estimated

00%

Competitive Landscape

2 competitors in Diffuse Large B-cell Lymphoma

INCYTafasitamab

View Full Landscape

Drug Information

Target Indication

Diffuse Large B-cell Lymphoma

Clinical Trial

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/7/2023

Columvi

Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline